Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL.

BACKGROUND Histologically, follicular lymphoma (FL) grades 1, 2 and 3A are composed of two distinct cell types, centroblasts and centrocytes. FL grade 3B is composed only of centroblasts and has been shown to differ in immunophenotype and genetics from FL that contain centrocytes. We aimed to understand the pathogenetic and clinical relation between FL grade 3A to FL grade 1/2 on the one hand and FL grade 3B on the other hand. PATIENTS AND METHODS Trial patients with long-term follow-up and diagnosis of FL grade 3 were selected and samples underwent a second central pathological review using a multiple-observer approach to assess grading. RESULTS Interobserver variability for diagnosing FL grade 3 was high. FL grade 3A frequently harbored areas of FL grade 1/2 within the same tissue specimen. FL grade 3B rarely coexisted with grade 1/2 or 3A, suggesting divergent pathogenesis. There was no statistically significant difference in outcome between 47 cases of FL grade 3A and 14 cases of grade 3B. Compared with grade 1/2 FL, both groups showed longer progression-free survival without late events, especially after immunochemotherapy; this outcome difference was retained after adjustment for clinical prognostic factors. The subgroup of FL grade 3A with an additional FL grade 1/2 component or a translocation t(14;18) showed a poorer outcome. In contrast, the FL grade 3A lacking t(14;18) and of localized stage resembled the pediatric type of FL and showed a very good outcome. FL3 with MYC breaks showed a poor outcome. CONCLUSIONS The results suggest that first-line immunochemotherapy might allow long-lasting remissions in a subgroup of FL grade 3A similar to diffuse large B-cell lymphoma. Within FL3A, prognostic subgroups can be identified by analyzing for coexisting FL1/2 and MYC breaks.

[1]  W. Klapper,et al.  [Recovery of paraffin blocks and central archiving : Experiences of the Kiel lymph node registry and the German study group for Hodgkin lymphoma]. , 2017, Der Pathologe.

[2]  A. Rosenwald,et al.  Similar clinical features in follicular lymphomas with and without breaks in the BCL2 locus , 2016, Leukemia.

[3]  Robert Kridel,et al.  Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. , 2015, The Lancet. Oncology.

[4]  A. Rosenwald,et al.  Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma , 2015, Leukemia.

[5]  B. Sander,et al.  Higher World Health Organization grades of follicular lymphoma correlate with better outcome in two Nordic Lymphoma Group trials of rituximab without chemotherapy , 2014, Leukemia & lymphoma.

[6]  H. Tsuda,et al.  Prognostic implications of histologic grade and intensity of Bcl-2 expression in follicular lymphomas undergoing rituximab-containing therapy. , 2013, Human pathology.

[7]  A. Rosenwald,et al.  MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. , 2013, Blood.

[8]  R. Siebert,et al.  Follicular Lymphomas in Children and Young Adults: A Comparison of the Pediatric Variant With Usual Follicular Lymphoma , 2013, The American journal of surgical pathology.

[9]  Gerard Lozanski,et al.  Inter-reader variability in follicular lymphoma grading: Conventional and digital reading , 2013, Journal of pathology informatics.

[10]  R. Siebert,et al.  Pediatric-type nodal follicular lymphoma: an indolent clonal proliferation in children and adults with high proliferation index and no BCL2 rearrangement. , 2012, Blood.

[11]  B. Sander,et al.  Clinical significance of the WHO grades of follicular lymphoma in a population‐based cohort of 505 patients with long follow‐up times , 2012, British journal of haematology.

[12]  A. Rosenwald,et al.  Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles , 2011, Haematologica.

[13]  W. Klapper,et al.  Follicular lymphoma: still Six characters in search of an author? , 2011, Leukemia & lymphoma.

[14]  Dirk Hasenclever,et al.  Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults. , 2011, Blood.

[15]  R. Gascoyne,et al.  Follicular non-Hodgkin lymphoma grades 3A and 3B have a similar outcome and appear incurable with anthracycline-based therapy. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  W. Klapper,et al.  Pediatric follicular lymphoma – a clinico-pathological study of a population-based series of patients treated within the Non-Hodgkin’s Lymphoma - Berlin-Frankfurt-Münster (NHL-BFM) multicenter trials , 2010, Haematologica.

[17]  S. Serrano,et al.  Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas , 2008, Haematologica.

[18]  Markus Loeffler,et al.  Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). , 2008, The Lancet. Oncology.

[19]  N. Shinton.  WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues , 2007 .

[20]  Carsten Schrader,et al.  Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: the German Low Grade Lymphoma Study Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  E. Hoster,et al.  Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas , 2006, Cancer.

[22]  D. Weisenburger,et al.  Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  N. Schmitz,et al.  Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t , 2005, Blood.

[24]  G. Lozanski,et al.  A clinicopathologic evaluation of follicular lymphoma grade 3A versus grade 3B reveals no survival differences. , 2004, Archives of Pathology & Laboratory Medicine.

[25]  E. Jaffe.  Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues , 2003 .

[26]  W. Chan,et al.  A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. , 2003, Blood.

[27]  A. Rosenwald,et al.  Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. , 2002, Blood.